EP Patent

EP0177893A2 — Sustained release dosage form based on highly plasticized cellulose ether gels

Assigned to Dow Chemical Co · Expires 1986-04-16 · 40y expired

What this patent protects

A solid sustained release dosage form, including a transdermal dosage form, is disclosed comprising a gel matrix containing HPMC and a major amount of a plasticizer therefor into which gel matrix is reversibly dispersed an active organic material, such as a pharmaceutically activ…

USPTO Abstract

A solid sustained release dosage form, including a transdermal dosage form, is disclosed comprising a gel matrix containing HPMC and a major amount of a plasticizer therefor into which gel matrix is reversibly dispersed an active organic material, such as a pharmaceutically active agent. When the dosage form is transdermal, a non-porous covering and means for adhering the dosage form to the skin of the patient are also present.

Drugs covered by this patent

Patent Metadata

Patent number
EP0177893A2
Jurisdiction
EP
Classification
—
Expires
1986-04-16
Drug substance claim
No
Drug product claim
No
Assignee
Dow Chemical Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.